Certified by Founder
Lodge
BioLoomics, Inc.
start up
United States
- Boulder, CO
- 20/09/2023
- Seed
- $8,700,000
BioLoomics is a preclinical stage biotechnology company leveraging directed evolution of antibodies in human cells to create target degrading antibodies. Our proprietary tech combines single-cell bioassay engineering, robotics, and ML.
#synbio #directedevolution #antibodies
- Industry Biotechnology Research
- Website https://www.bioloomics.com/
- LinkedIn https://www.linkedin.com/company/bioloomics/about/
EnerVenue | $300,000,000 | (Apr 3, 2026)
Acurion, Inc. | $4,300,000 | (Apr 3, 2026)
Gander Robotics | $1,100,000 | (Apr 3, 2026)
daydream | $15,000,000 | (Apr 3, 2026)
Numos | $4,250,000 | (Apr 3, 2026)
Alien | $7,100,000 | (Apr 3, 2026)
Monarch Quantum | $55,000,000 | (Apr 3, 2026)
Sona(UK) | $45,000,000 | (Apr 2, 2026)
Linx Security | $50,000,000 | (Apr 2, 2026)
Earlyasset | $2,000,000 | (Apr 2, 2026)
Rowan(US) | $3,300,000 | (Apr 2, 2026)
Whirl AI | $8,900,000 | (Apr 2, 2026)